ZOLANCT07780968
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
StatusNot Yet Recruiting
PhaseNot specified
SponsorJazz Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 1, 2026 to Nov 30, 2026
- Notable Eligibility criteria expanded, about 8 words
- Secondary endpoints: details revised at 4 of 18 entries
- Notable Eligibility criteria shortened, about 5 words
- Secondary endpoints: details revised at 1 of 18 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Average age of participants
Timeframe: Baseline
Patient demographics
Timeframe: Baseline
Clinical characteristics
Timeframe: Baseline
Average BMI
Timeframe: Baseline
Average BSA
Timeframe: Baseline
Heart Function
Timeframe: Baseline
Diagnostic history
Timeframe: Baseline
Treatment history
Timeframe: Baseline
Biomarkers
Timeframe: Baseline
Number of participants taking a treatment in combination with first line zanidatamab-containing therapy
Timeframe: Up to 5 years
Average dose of treatment
Timeframe: Up to 5 years
Cycles of treatment
Timeframe: Up to 5 years
Average duration of first line zanidatamab-containing therapy
Timeframe: Up to 5 years
Number of participants at each HER2 status results after initiation of first line zanidatamab-containing therapy
Timeframe: Up to 5 years
Average chemotherapy dose adjustment
Timeframe: Up to 5 years
Duration of treatment interruption
Timeframe: Up to 5 years
Number of participants at each subsequent line of therapy after treatment discontinuation
Timeframe: Up to 5 years
Reason of treatment adjustment
Timeframe: Up to 5 years
Secondary (18)
Incidence of AESI
Duration of the AESI
Time (by treatment cycle) for the onset of AESI
Time (by treatment cycle) of dose adjustment
Number of participants that adhered to prescribed diarrhea prophylaxis
Show 13 moreShow less
Time (by treatment cycle) of additional supportive therapy
Causality of AESI
Resolution of AESI
Number of participants at each additional supportive therapy
Number of new metastatic sites
Real world Objective Response Rate (rwORR)
Real world Tumor Response (rwR)
Real world Disease Progression (rwP)
Real world Progression Free Survival (rwPFS)
Real world Progression Free Survival on Second line Therapy (rwPFS2)
Real world Duration of Response (rwDoR)
Overall survival
EORTC IL 66 scores
Arms and interventions
Zanidatamab-containing Therapy
Participants with HER2-positive locally advanced or metastatic GEA initiating a zanidatamab-containing therapy as first line treatment as part of standard-of-care treatment
Drugs: Zanidatamab
Sites
2 sites in 1 country